Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session: Thoracic cancers

LBA6 - Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer: A multicentre, open-label, randomized phase III study


02 Dec 2022


Proffered Paper session: Thoracic cancers


Targeted Therapy

Tumour Site

Non-Small Cell Lung Cancer


Shun Lu


Annals of Oncology (2022) 33 (suppl_9): S1553-S1559. 10.1016/annonc/annonc1133


S. Lu1, J. Zhou2, H. Jian1, L. Wu3, Y. Cheng4, Y. Fan5, J. Fang6, G. Chen7, Z. Zhang8, D. Lv9, L. Jiang10, R. Wu11, X. Jin12, X. Zhang13, J. Zhang14, G. Sun15, D. Huang16, J. Cui17, R. Guo18, L. Ding19

Author affiliations

  • 1 Department Of Oncology, Shanghai Chest Hospital, 200030 - Shanghai/CN
  • 2 Respiratory Medicine, The First Affiliated Hospital of Medical School of Zhejiang University, 310003 - Hangzhou/CN
  • 3 Department Of Thoracic Medical Oncology Ii, Hunan Cancer Hospital, 410013 - Changsha/CN
  • 4 Department Of Oncology, Jilin Cancer Hospital, 130012 - Changchun/CN
  • 5 Thoracic Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences Zhejiang Cancer Hospital, 310022 - Hangzhou/CN
  • 6 Thoracic Surgeon, Beijing Cancer Hospital, 100142 - Beijing/CN
  • 7 Department Of Respiratory Medical Oncology, Tumor Hospital of Harbin Medical University, 150081 - Harbin/CN
  • 8 Depertment Of Medical Respiratory, Anhui Provincial Cancer Hospital, 230001 - Hefei/CN
  • 9 Breath Internal Medicine, Taizhou Hospital of Zhejiang Province, 317000 - Taizhou/CN
  • 10 Department Of Respiratory Medicine, Shanghai Chest Hospital, 200030 - Shanghai/CN
  • 11 Second Oncology Ward, ShengJing Hospital of China Medical University, 110020 - Shenyang/CN
  • 12 Department Of Oncology, General Hospital of Ningxia Medical University, 750004 - Yinchuan/CN
  • 13 Internal Medicine Oncology, Nantong Tumor Hospital, 226361 - Nantong/CN
  • 14 Dept.of Radiation And Medical Onclogy, Zhongnan Hospital of Wuhan University, 430071 - Wuhan/CN
  • 15 Depertment Of Medical Respiratory, The First Affiliated Hospital of Anhui Medical University, 230022 - Hefei/CN
  • 16 Department Of Medical Oncology, Liuzhou Worker's Hospital, 545005 - Liuzhou/CN
  • 17 Oncology Department, The First Hospital of Jilin University, 130021 - Changchun/CN
  • 18 Oncology Department, Jiangsu Province Hospital, 210029 - Nanjing/CN
  • 19 Department Of Medicine, Betta Pharmaceuticals Co.,Ltd., 311100 - Hangzhou/CN


Login to access the resources on OncologyPRO.

Abstract LBA6


Befotertinib (D-0316), a novel highly selective oral third-generation EGFR-TKI, exhibited encouraging antitumor activity in a pivotal phase II study (NCT03861156) in EGFR T790M mutation-positive patients (pts). This phase III, open-label, randomized trial was conducted to compare the efficacy and safety of befotertinib versus icotinib as first-line treatment in pts with previously untreated, locally advanced or metastatic NSCLC with EGFR-sensitizing mutation (Del19 or L858R).


Eligible stage IIIB/IIIC/IV NSCLC pts with confirmed EGFR Del19 or L858R mutation were randomly assigned (1:1) to receive either befotertinib (75–100 mg once daily) or icotinib (125 mg thrice daily) as first-line therapy. The primary endpoint was progression free survival (PFS) assessed by independent central review (IRC). Second endpoints included objective response rate (ORR), disease control rate (DCR), duration of response (DOR), overall survival (OS) by IRC, and safety.


Between Dec 24, 2019 and Dec 28, 2020, 362 pts were randomized to receive befotertinib (n=182) and icotinib (n=180). At a median follow-up of 20.6 months, median PFS by IRC was 22.1 months for befotertinib and 13.8 months for icotinib (HR 0.49 [95% CI 0.36-0.68]; p<0.0001). ORR was 75.8% and 78.3%, DCR was 94.5% and 98.3% for befotertinib and icotinib arms, respectively. Median DOR was 12.4 months for icotinib arm but not reached for befotertinib arm. OS data were immature in both treatment arms. Median treatment duration was 16.4 months with befotertinib versus 11.1 months with icotinib. Grade≥3 treatment-emergent adverse events (TEAEs) were observed in 86 pts (47.3%) for befotertinib arm and in 54 (30.0%) for icotinib arm. Drug-related deaths occurred in 2 (1.1%) versus 1 (0.6%) pts in the befotertinib versus icotinib arm.


Befotertinib demonstrated superior efficacy compared with icotinib in the first-line treatment for advance pts with EGFR mutation-positive NSCLC, with an acceptable safety profile.

Clinical trial identification


Editorial acknowledgement

Editorial assistance in the writing of the abstract that was provided by Betta Pharmaceuticals Co., Ltd., Hangzhou, China.

Legal entity responsible for the study

Betta Pharmaceuticals Co., Ltd., Hangzhou, China.


Betta Pharmaceuticals Co., Ltd., Hangzhou, China.


S. Lu: Financial Interests, Institutional, Invited Speaker: AstraZeneca, Hansoh, Hengrui, Roche; Financial Interests, Institutional, Advisory Board: AstraZeneca, Boehringer lngelheim, GenomiCare, Hutchison MediPharma, InventisBio Co.Ltd, Menarini, Prizer, Roche, Yuhan Corporation, ZaiLab; Non-Financial Interests, Personal, Research Grant: AstraZeneca, BeiGene, BMS, Hansoh, Hengrui, Hutchison, Lilly Suzhou Pharmaceutical Co., Ltd., Roche. L. Ding: Financial Interests, Personal, Stocks/Shares: Betta Pharmaceuticals Co., Ltd. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.